Atlas Trials

Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer

Clinical trial NCT03111901 · WITHDRAWN

Trial details

NCT number
NCT03111901
Sponsor
William Grosh, MD
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Carcinoma, Renal CellMelanoma
Start date
2018-10-29
Primary completion
2023-10-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.